Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorec... (%) dermatology-other (27% 6%) and stomat...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer

Date:10/2/2007

%), dermatology-other (27%, 6%), and stomatitis (25%, 10%).

About ImClone Systems

ImClone Systems Incorporated is a fully integrated biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey. For more information about ImClone Systems, please visit the Company's web site at http://www.imclone.com.

ERBITUX(R) is a registered trademark of ImClone Systems Incorporated.

Certain matters discussed in this news release may constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Many of these factors are beyond the company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the company and the statements contained in this news release can be found in the company's filings with the Securities and Exchange Commission, including quarterly reports on Form 10-Q, current reports on Form 8-K and annual reports on Form 10-K. For forward-looking statements in this news release, the company claims the protection of the safe harbor for forward-looking statements contained in t
'/>"/>

SOURCE Bristol-Myers Squibb Company; ImClone Systems Incorporated
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
5. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
6. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal Women with Early Breast Cancer Receiving Treatment with Tamoxifen
9. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
10. Synta Presents Results for STA-4783 in Metastatic Melanoma Showing Improvement in Overall Survival
11. Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

Post Your Comments:

(Date:11/20/2009)...swire/ -- Reportlinker.com announces that a new ma.... ,, Global Markets for Assisted Reproductive ...p0164742/Global-Markets-for-Assisted-Reproductive-...dium=pr&utm_campaign=prnewswire ,, Global..., 15 Countries in Europe and Japan. This report in...

(Date:11/20/2009)...ov. 20 Boston Scientific...t has received 510(k) clearance from the U.S. Food...l to market its WallFlex® Fully Covered Esoph...eal strictures (obstructions) caused by tumors in ...eal cancer. ,, (Photo: http://www.newscom.co...

(Date:11/20/2009)...re-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX )...ef Executive Officer, and Greg Browne, Chief Finan...r Jaffray Health Care Conference in New York on We...nference session and webcast will be audio only an...ay will host a webcast of the presentation live an...

Breaking Medicine Technology:Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2 Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2 Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3 Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4 Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2 Health Care Reform Could Be Obamas Toughest Challenge 49596 1 Health Care Reform Could Be Obamas Toughest Challenge 49596 2 Health Care Reform Could Be Obamas Toughest Challenge 49596 3 Health Care Reform Could Be Obamas Toughest Challenge 49596 4 SailPoint and Cyber Ark Partner to Prevent Insider Threats 49592 1 SailPoint and Cyber Ark Partner to Prevent Insider Threats 49592 2 SailPoint and Cyber Ark Partner to Prevent Insider Threats 49592 3 SailPoint and Cyber Ark Partner to Prevent Insider Threats 49592 4 Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer 49588 1 Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer 49588 2 Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer 49588 3

[0] Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 [0] Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent [0] Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference

...RNewswire-USNewswire/ -- Evidence is,accumulating ...,reports the June 2007 issue of Harvard Women,s He...50 and over who regularly took,antidepressants cal...) had double the rate of fractures as people not u...pression itself as a source,of endocrine changes t...

...07 - Algeta ASA (OSE: ALGETA), the,Norwegian cance...Oslash;yvind Bruland, of the Norwegian Radium Hosp...oster and Discussion entitled,"Radium-223 in the ...e cancer (HRPC): Results from a randomized,placeb...iety of,Clinical Oncology,s annual meeting (1-5 Ju...

Other Medicine Technology:Antidepressant Use May Boost Fracture Risk, From Harvard Women's,Health Watch 2 Algeta to Present Phase II Clinical Study Data for Alpharadin in,Prostate Cancer at ASCO 2

Antidepressant Use May Boost Fracture Risk, From Harvard Women's,Health Watch Algeta to Present Phase II Clinical Study Data for Alpharadin in,Prostate Cancer at ASCO

(Date:11/20/2009)...s in children with chronic kidney disease often fa...fice visits increasing a child,s risk for serious...Hopkins Children,s Center and other institutions. ...rnal of American Society of Nephrology. , Rese...ned during regular doctor visits to readings obtai...

(Date:11/20/2009)...ed out of Dallas, TX, the new addition to blue sky... are made in the USA. , A...rubs is an independent medical scrubs brand which ...on and distribution of hospital uniforms and surgi...ucts via their online boutique, the Austin, TX bus...

(Date:11/20/2009)...d buying 90-day supply, study finds , , ...-month supply of prescription drugs is up to one-t...ding to a new study. , U.S. researchers analyze...n 2000 and 2005, and found that patients who bough...ly saved an average 29 percent in out-of-pocket co...

(Date:11/20/2009)...h and is expected to continue, CDC says, , ...as of the United States are seeing declines in H1N...id Friday, and while the disease remains widesprea...orted last week. , "We are beginning to see som...y, but there is still a lot of influenza everywher...

(Date:11/20/2009)...addresses increased food insecurity as many face p...e-USNewswire/ -- Project Bread, the state,s leadin...its upcoming annual status report on hunger in the... this report, caused by high unemployment, point t...th hunger. Food insecurity has found its way into ...

Breaking Medicine News(10 mins):Health News:High blood pressure easy to miss in children with kidney disease 2 Health News:Blue Sky Scrubs Secures a Second Texas Manufacturer 2 Health News:Three-Month Supply Lowers Drug Costs 2 Health News:Swine Flu Declining in Some Parts of U.S. 2 Health News:Swine Flu Declining in Some Parts of U.S. 3 Health News:554,000 in Massachusetts Struggle to Put Food on the Table 2 Health News:554,000 in Massachusetts Struggle to Put Food on the Table 3 Health News:554,000 in Massachusetts Struggle to Put Food on the Table 4

[0] High blood pressure easy to miss in children with kidney disease [0] Blue Sky Scrubs Secures a Second Texas Manufacturer [0] Three-Month Supply Lowers Drug Costs [0] Swine Flu Declining in Some Parts of U.S.[0] 554,000 in Massachusetts Struggle to Put Food on the Table

...th American application activity for individually ...ry, year-over-year, according to the MIB Life Ind...ruary 2009 was up +12.9%. Year-to-date (YTD), Nor... Index methodology rather than a change in underly...

...Newswire-Asia-FirstCall/ -- China Sky One,Medical,...Nasdaq: CSKI ), a,leading fully integrated pharm... in the People,s Republic of China (,PRC,), today ...es. , Policresulen vaginal suppositories are i...

...Revenue: $35.7 million, up 19% from $29.9 million ...4,07 , , LAWRENCE, Mass., March 12 NxStage Medic... of innovative dialysis products, today reported f...f its guidance range and gross margins well within...

...hina, March 12 /PRNewswire-Asia-FirstCall/ --,Chin...etin Board: CPHI) which,develops, manufactures, an...na,today announced it will release its Fourth Quar...8, 2009 to discuss these results. , Ms. Zhilin...

...ruism as Key to Man,s Evolution and Well-Being , ... has teamed with the National Science Foundation, ...earch, and Washington University Center for the ...rday, March 14, "Man The Hunted" includes panels a...

...arch 12 /PRNewswire-Asia-FirstCall/ -- Shengtai,Ph...engtai" or "the Company"),a leading manufacturer a...de,glucose products in China, today announced that... "The demand for medical transfusion products ha...

MIB Life Index Reports North American Life Insurance Activity up 1.1% in February China Sky One Medical, Inc. Obtains SFDA Approval for Policresulen Vaginal Suppositories NxStage Reports Fourth Quarter and Full Year 2008 Financial Results China Pharma Holdings, Inc. to Host Fourth Quarter 2008 Earnings Conference Call at 8:30 a.m. EDT Wednesday March 18, 2009 Anthropedia Foundation Co-Hosting 'Man The Hunted' Conference Recent Industry Developments Reaffirm Positive Glucose Industry Outlook

...onal reference laboratory and a worldwide leader i...ARUP offers an extensive test menu of highly compl...ic pathology. Owned by the University of Utah, ARU...the nation's university teaching hospitals and chi...

Medicine Products:

Tzanck Smear Typhus Fever Antibody, IgG Typhus Fever Antibody, IgM Type & RH

Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorec...(%) dermatology-other (27% 6%) and stomat...),Health